Skip to content

Effect of mycophenolate mofetil on oral erosive lichen planus

Effect of mucoadhesive form of mycophenolate mofetil on oral erosive lichen planus lesions

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013011611976N2
Enrollment
27
Registered
2013-05-23
Start date
2013-05-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral lichen planus. lichen planus

Interventions

Intervention 1: Intervention side: mucoadhesive of mycophenolate mofetil 2%,for 1month, twice daily, after breakfast at 10 & in the afternoon at 5. Intervention 2: Control side: orabase, for 1month,tw
Treatment - Drugs
Intervention side: mucoadhesive of mycophenolate mofetil 2%,for 1month, twice daily, after breakfast at 10 & in the afternoon at 5.
Control side: orabase, for 1month,twice daily, after breakfast at 10 & in the afternoon at 5.

Sponsors

Deputy of Research of Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with erosive oral lichen planus with clinical manifestations and histopathological criteria; existence of two lesions with similar clinical appearance on the right and left buccal mucosa; patients older than 18 years of age. Exclusion criteria: not received any treatment for the lesions for at least 4 weeks ago; any factor that cause lichenoid reaction; any systemic or dermal disease which affects immune system of the patient; incidence of any adverse effect of mycophenolate mofetil during the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Size of lesion. Timepoint: Baseline and after 1 month. Method of measurement: Measured by digital culis.;Pain and burning sensation. Timepoint: Baseline and weekly for one month. Method of measurement: The oral lesions will be clinically graded based on VAS grading scale.

Secondary

MeasureTime frame
Adverse effects. Timepoint: Evrey week for 1 month. Method of measurement: Clinical examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNegin Samiei

Dental Faculty of Tabriz University of Medical Sciences

n.samiei@yahoo.com+98 41 1335 5965

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026